Jackson Peter Philip James, Wijeyesekera Anisha, Rastall Robert Adrian
Department of Food and Nutritional Sciences, University of Reading, Reading, UK.
Gut Microbiome (Camb). 2022 Sep 7;3:e9. doi: 10.1017/gmb.2022.8. eCollection 2022.
Human milk oligosaccharides (HMOs) are a class of structurally diverse and complex unconjugated glycans present in breast milk, which act as selective substrates for several genera of select microbes and inhibit the colonisation of pathogenic bacteria. Yet, not all infants are breastfed, instead being fed with formula milks which may or may not contain HMOs. Currently, formula milks only possess two HMOs: 2'-fucosyllactose (2'FL) and lacto--neotetraose (LNnT), which have been suggested to be similarly effective as human breast milk in supporting age-related growth. However, the evidence regarding their ability to beneficially reduce respiratory infections along with altering the composition of an infant's microbiota is limited at best. Thus, this review will explore the concept of HMOs and their metabolic fate, and summarise previous and clinical data regarding HMOs, with specific regard to 2'FL and LNnT.
人乳寡糖(HMOs)是一类结构多样且复杂的未结合聚糖,存在于人乳中,可作为几种特定微生物属的选择性底物,并抑制病原菌的定殖。然而,并非所有婴儿都进行母乳喂养,而是采用可能含有或不含有HMOs的配方奶喂养。目前,配方奶仅含有两种HMOs:2'-岩藻糖基乳糖(2'FL)和乳糖-N-新四糖(LNnT),有人认为它们在支持与年龄相关的生长方面与母乳具有相似的功效。然而,关于它们在有益减少呼吸道感染以及改变婴儿微生物群组成方面的能力,相关证据充其量也很有限。因此,本综述将探讨HMOs的概念及其代谢命运,并总结以往的研究和关于HMOs的临床数据,特别是针对2'FL和LNnT。